Among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), younger age, elevated blood eosinophil count, and increased comorbidity were all associated with nasal polyp surgery, according to findings presented at the AAO-HNSF 2021 Annual Meeting.
This retrospective cohort study aimed to assess the association between disease burden and surgery status in patients with nasal polyps. The authors utilized medical and pharmacy claims obtained from the Optum Clinformatics Data Mart Database to obtain data on patients at least 18 years old diagnosed with CRSwNP between January 1, 2008 and March 31, 2019.
Patient demographics, blood eosinophil counts, comorbidities, nasal polyp surgery setting, and health care resource utilization and costs were all included in the analysis. The authors noted that if the time between 2 surgeries was at least 180 days, the surgery was considered to be new.
The estimated standardized prevalence of nasal polyps was reported to be 0.186% (95% CI, 0.163-0.208). Of the total 119,357 CRSwNP patients identified, 28.3% had at least 1 surgery during the observation period (median observation duration, 29.0 months). Of these patients, 2.7% required at least 2 surgeries.
“Patients with 1 or greater vs 0 surgeries were younger (mean age: 51.6 vs 53.5 years), had slightly higher baseline [blood eosinophil counts] (eosinophil 150 cells/µL or greater: 67.0% vs 63.9% patients), and had a greater burden of comorbidities (mean Quan-Charlson Comorbidity Index score: 0.52 vs 0.40 points), with a higher proportion with asthma (37.8% vs 21.8%) and allergic rhinitis (34.0% vs 15.1%).”
During follow-up, all-cause and CRSwNP-related health care resource utilization increased as the number of surgeries went up (driven by outpatient visits). Medical (hospitalizations, emergency department visits, outpatient visits, other visits) and pharmacy costs (CRSwNP-related treatment prescriptions) also increased as the number of surgeries increased.
Based on their findings, the authors concluded that “further research is needed on the unmet treatment needs of patients with CRSwNP, particularly for those with recurrent disease who do not respond to standard therapies.”
Disclosure: Some authors have declared affiliations with or received funding from the pharmaceutical industry. Please refer to the original study for a full list of disclosures.
Benson VS, Germain G, Duh MS, Yang S, Silver J. A real-world characterization of nasal polyp patient burden. Presented at: AAO-HNSF 2021 Annual Meeting; October 3-6, 2021; Los Angeles, CA.
This article originally appeared on MPR